Cure My Disease

Don't miss your cure!

 Log in / Sign up

Researchers track Long-Term safety of experimental eye cancer drug

NCT ID NCT03941379

Knowledge-focused Sponsor: Aura Biosciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This registry follows 63 patients with choroidal melanoma or early eye lesions who were treated with the experimental drug bel-sar in earlier studies. The goal is to monitor long-term safety, side effects, and any spread of the disease over time. Participants are not receiving new treatment but are observed through standard medical checkups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bel-sar (AU-011)
What this could lead to
If successful, this registry will provide important long-term safety data that could support the future use of bel-sar as a treatment for choroidal melanoma.
What could go wrong
This is an observational registry, not a treatment trial, so it does not test whether bel-sar works. It only collects data from a small number of patients who already received the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

63 people

The number who actually took part.

Started

Mar 2019

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects with primary Indeterminate Lesions or Choroidal Melanoma who participated in previous Aura Biosciences sponsored clinical trial.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have been clinically diagnosed with primary IL or CM at the time of entry to a previous Aura Biosciences sponsored clinical trial. * Have received AU-011 bel-sar treatment in a previous Aura Biosciences sponsored clinical trial. * Have completed the exit visit of the previous Aura Biosciences sponsored clinical trial within 1 year of Day 1 (≤365 days) of enrollment into the Registry. Exclusion Criteria: \- None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Choroidal melanoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant choroid melanoma Uveal Melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Choroidal melanoma Indeterminate lesions of eye

Contacts and locations

Locations

  • Associated Retinal Consultants, PC

    Royal Oak, Michigan, 48073, United States

  • Byers Eye Institute at Stanford University

    Palo Alto, California, 94303, United States

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Massachusetts Eye and Ear Infirmary

    Boston, Massachusetts, 02114, United States

  • Oregon Health & Science University Casey Eye Institute

    Portland, Oregon, 97239, United States

  • Retina Associates SW, P.C.

    Tucson, Arizona, 85710, United States

  • Retina Center

    Minneapolis, Minnesota, 55404, United States

  • Retina Consultants of Carolina, PA

    Greenville, South Carolina, 29605, United States

  • Retina Consultants of Houston

    Houston, Texas, 77030, United States

  • Retina Consultants of Sacramento

    Sacramento, California, 95825, United States

  • St. Thomas Health / Tennessee Retina, PC

    Nashville, Tennessee, 37203, United States

  • Texas Retina Associates

    Dallas, Texas, 75231, United States

  • UCLA Jules Stein Eye Institute

    Los Angeles, California, 90095, United States

  • University of Wisconsin

    Madison, Wisconsin, 53705, United States

  • W. K. Kellogg Eye Center, University of Michigan

    Ann Arbor, Michigan, 48105, United States

  • Wills Eye Hospital

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.